This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

AnaptysBio Past Earnings Performance

Past criteria checks 0/6

AnaptysBio's earnings have been declining at an average annual rate of -19.2%, while the Biotechs industry saw earnings growing at 29.1% annually. Revenues have been growing at an average rate of 22.1% per year.

Key information

-19.25%

Earnings growth rate

-18.65%

EPS growth rate

Biotechs Industry Growth	17.04%
Revenue growth rate	22.06%
Return on equity	-35.56%
Net Margin	-5.64%
Last Earnings Update	31 Dec 2025

Recent past performance updates

No updates

Recent updates

No updates

Revenue & Expenses Breakdown

How AnaptysBio makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:ANAB.V Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses
31 Dec 25	235	-13	51
30 Sep 25	169	-85	45
30 Jun 25	123	-133	45
31 Mar 25	112	-141	44
31 Dec 24	91	-145	42
30 Sep 24	57	-166	42
30 Jun 24	30	-170	42
31 Mar 24	23	-163	43
31 Dec 23	17	-164	42
30 Sep 23	15	-148	41
30 Jun 23	13	-144	37
31 Mar 23	11	-137	37
31 Dec 22	10	-129	37
30 Sep 22	4	-135	29
30 Jun 22	24	-108	29
31 Mar 22	53	-76	23
31 Dec 21	63	-58	21
30 Sep 21	122	8	21
30 Jun 21	101	-9	21
31 Mar 21	71	-30	20
31 Dec 20	75	-20	19
30 Sep 20	18	-74	18
30 Jun 20	18	-81	17
31 Mar 20	23	-84	16
31 Dec 19	8	-97	16
30 Sep 19	5	-94	16
30 Jun 19	10	-79	16
31 Mar 19	5	-69	16
31 Dec 18	5	-62	16
30 Sep 18	8	-52	14
30 Jun 18	3	-45	13
31 Mar 18	10	-34	11
31 Dec 17	10	-30	9
30 Sep 17	10	-27	8
30 Jun 17	13	-19	6
31 Mar 17	12	-15	5
31 Dec 16	17	-4	4
30 Sep 16	18	-4	4
30 Jun 16	19	-4	4
31 Mar 16	18	-6	4
31 Dec 15	18	-5	4
30 Sep 15	17	-2	3
30 Jun 15	19	0	3

Quality Earnings: ANAB.V is currently unprofitable.

Growing Profit Margin: ANAB.V is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ANAB.V is unprofitable, and losses have increased over the past 5 years at a rate of 19.2% per year.

Accelerating Growth: Unable to compare ANAB.V's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANAB.V is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50.1%).

Return on Equity

High ROE: ANAB.V has a negative Return on Equity (-35.56%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/20 12:30
End of Day Share Price	2026/04/17 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AnaptysBio, Inc. is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Neena Bitritto-Garg	Baird
Etzer Darout	Barclays
Michael King	Citizens JMP Securities, LLC